Special Issue "Immunology in COVID-19 Disease: From Pathophysiology to Novel Therapeutic Approaches"
Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 78636
Interests: regulatory T cells; immune dysregulation; COVID-19; cellular therapy; CAR-T cell generation
Special Issues, Collections and Topics in MDPI journals
Since December 2019, a novel coronavirus, called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread worldwide, causing the coronavirus disease 2019 (COVID-19). The COVID-19 pandemic has compromised the entire world at the socioeconomic level. To eradicate the virus spreading and virulence, it is crucial to acquire strong and long-lasting anti-SARS-CoV-2 immunity, either by natural infection or vaccination. Severe COVID-19 is deeply studied, although individuals represent a low percentage of developing the disease, and an even lower proportion develop a fatal infection. Nevertheless, even people with mild symptoms may have long-term sequelae, and it is unknown if these long-term symptoms could be associated with future re-infection or subsequent pathogenesis. Therefore, among the most important questions is that concerning the quality and durability of the immune response after natural infection, which will help develop upcoming vaccines or new therapeutic strategies. This Special Issue aims to include research on the pathophysiological aspects of COVID-19, its immunological features, and possible new therapeutic hypotheses. Particular attention will be given to immune dysregulation both during and after viral infection and new therapeutic approaches. All clinical and basic research, including gender, long-term symptoms, individual clinical background, genetic susceptibility, symptom severity, and mechanistic of viral replication and spreading, will be considered.
Dr. Marjorie Pion
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- pathophysiology of COVID-19
- immune dysregulation
- Long COVID-19
- individual factors